CytoMed Therapeutics Limited Ordinary Shares Financial Flexibility Index
CytoMed Therapeutics Limited Ordinary Shares financial flexibility index. CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Financial Flexibility Index of -1.55x as of December 2025. Free cash flow of $-1.75 Million (operating CF $-2.05 Million minus capex $297.96K) represents -2% of total liabilities ($1.13 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
Financial flexibility index of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. Historical Financial Flexibility Index trend for CytoMed Therapeutics Limited Ordinary Shares across 7 annual periods. Explore CytoMed Therapeutics Limited Ordinary Sh cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
CytoMed Therapeutics Limited Ordinary Shares Financial Flexibility Index by Year (2019–2025)
CytoMed Therapeutics Limited Ordinary Shares financial flexibility index by year from 2019 to 2025. Year-by-year free cash flow to debt coverage for CytoMed Therapeutics Limited Ordinary Shares. For the full cash flow conversion analysis, see GDTC cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.65x | $-2.99 Million | $-3.70 Million | $1.13 Million | ▼ -106.9% |
| 2024 | -1.28x | $-1.31 Million | $-2.71 Million | $1.02 Million | ▲ +58.6% |
| 2023 | -3.09x | $-3.48 Million | $-3.54 Million | $1.13 Million | ▼ -1449.8% |
| 2022 | -0.20x | $-928.92K | $-1.40 Million | $4.66 Million | ▲ +38.5% |
| 2021 | -0.32x | $-1.13 Million | $-1.72 Million | $3.50 Million | ▼ -61.5% |
| 2020 | -0.20x | $-671.13K | $-916.39K | $3.35 Million | ▼ -137.1% |
| 2019 | 0.54x | $544.52K | $-640.52K | $1.01 Million | — |